Grace Therapeutics (GRCE) Competitors $3.26 +0.18 (+5.84%) As of 08/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. CTNM, KRRO, TIL, RAPT, ACTU, CYBN, DERM, BTMD, MEIP, and CCCCShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Contineum Therapeutics (CTNM), Korro Bio (KRRO), Instil Bio (TIL), Rapt Therapeutics (RAPT), Actuate Therapeutics (ACTU), Cybin (CYBN), Journey Medical (DERM), biote (BTMD), MEI Pharma (MEIP), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Contineum Therapeutics Korro Bio Instil Bio Rapt Therapeutics Actuate Therapeutics Cybin Journey Medical biote MEI Pharma C4 Therapeutics Grace Therapeutics (NASDAQ:GRCE) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has preferable valuation & earnings, GRCE or CTNM? Grace Therapeutics has higher earnings, but lower revenue than Contineum Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$9.57M-$0.86-3.79Contineum Therapeutics$50M4.14-$42.26M-$2.20-3.35 Which has more risk & volatility, GRCE or CTNM? Grace Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Do insiders and institutionals believe in GRCE or CTNM? 6.1% of Grace Therapeutics shares are held by institutional investors. 11.1% of Grace Therapeutics shares are held by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is GRCE or CTNM more profitable? Grace Therapeutics' return on equity of -20.36% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -20.36% -18.09% Contineum Therapeutics N/A -29.75%-28.08% Do analysts recommend GRCE or CTNM? Grace Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 268.10%. Contineum Therapeutics has a consensus target price of $22.50, suggesting a potential upside of 204.88%. Given Grace Therapeutics' higher probable upside, equities analysts plainly believe Grace Therapeutics is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media prefer GRCE or CTNM? In the previous week, Grace Therapeutics had 5 more articles in the media than Contineum Therapeutics. MarketBeat recorded 10 mentions for Grace Therapeutics and 5 mentions for Contineum Therapeutics. Grace Therapeutics' average media sentiment score of 1.27 beat Contineum Therapeutics' score of 0.93 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGrace Therapeutics beats Contineum Therapeutics on 8 of the 15 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.08M$3.15B$5.75B$9.81BDividend YieldN/A2.21%3.91%4.13%P/E Ratio-3.7920.8931.1125.06Price / SalesN/A325.81433.9099.62Price / CashN/A42.6136.7858.67Price / Book0.718.659.086.18Net Income-$9.57M-$54.65M$3.26B$265.11M7 Day Performance1.24%6.56%7.38%4.22%1 Month Performance-2.69%4.82%4.21%0.77%1 Year PerformanceN/A15.81%30.29%24.69% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.8541 of 5 stars$3.26+5.8%$12.00+268.1%N/A$45.08MN/A-3.79N/AEarnings ReportAnalyst RevisionCTNMContineum Therapeutics3.4867 of 5 stars$7.26+4.5%$22.50+209.9%-56.9%$179.81M$50M-3.3031Short Interest ↓KRROKorro Bio1.4495 of 5 stars$19.88+5.0%$86.83+336.8%-53.9%$177.77M$2.27M-2.0470Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionTILInstil Bio3.0977 of 5 stars$28.25+4.7%$119.00+321.2%+176.7%$176.89MN/A-2.19410News CoverageEarnings ReportAnalyst ForecastRAPTRapt Therapeutics4.6085 of 5 stars$11.25+6.1%$21.57+91.7%-33.0%$175.30M$1.53M-0.7980Analyst ForecastACTUActuate Therapeutics2.251 of 5 stars$8.22-3.6%$20.50+149.4%-6.7%$174.61MN/A0.0010News CoverageEarnings ReportCYBNCybin2.4455 of 5 stars$7.17-5.7%$85.00+1,085.5%N/A$169.14MN/A-1.6450News CoverageDERMJourney Medical1.6939 of 5 stars$7.26+0.1%$10.83+49.2%+56.9%$168.89M$56.13M-19.1190News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionBTMDbiote2.5183 of 5 stars$2.98-2.9%$6.00+101.3%-49.6%$167.96M$197.19M3.31194MEIPMEI Pharma2.1516 of 5 stars$4.90-4.7%N/A+51.4%$166.37MN/A-1.03100Short Interest ↑Gap UpCCCCC4 Therapeutics1.5963 of 5 stars$2.35+0.9%$8.00+240.4%-57.9%$165.83M$35.58M-1.49150 Related Companies and Tools Related Companies Contineum Therapeutics Alternatives Korro Bio Alternatives Instil Bio Alternatives Rapt Therapeutics Alternatives Actuate Therapeutics Alternatives Cybin Alternatives Journey Medical Alternatives biote Alternatives MEI Pharma Alternatives C4 Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access